register

News & Trends - Pharmaceuticals

GenesisCare inks two strategic agreements in cancer medicine

Health Industry Hub | March 31, 2023 |

Pharma News: Theranostics have unprecedented value to diagnose and treat cancers, and a number of novel theranostics are under development and expected to enter clinical trials and care in the near future. In the lead up to World Theranostics Day this Friday, 31st March, GenesisCare has announced two strategic agreements to identify and proactively pursue clinical research opportunities in the fields of molecular imaging and theranostics.

GenesisCare’s Chief Scientific Officer, Theranostics, Research & Insights, Dr Danielle Meyrick, said “Over the last decade we have made significant progress in the advancement of theranostics in Australia, both in terms of the development of new therapies and advanced imaging technologies, as well as the emergence of a network of nuclear medicine physicians and physicists with the expertise and deep knowledge base to deliver the best possible care for patients.”

“GenesisCare hopes to unlock the full potential of theranostics both here in Australia and abroad, to ensure the patient benefits of these recent therapeutic and technological advancements are fully realised,” Dr Meyrick.

Professor Rodney Hicks, PreMIT Founder, Chairman, and Chief Medical Officer, said “PreMIT is delighted to be partnering with GenesisCare, who share our vision of democratising and scaling patient access to theranostics and precision medicine worldwide.”

“Together, PreMIT and GenesisCare are seeking to develop a differentiated clinical trial capability to increase patient access to novel therapies, drive greater collaboration within the academic and biotechnology ecosystem, and facilitate efficient and integrated research data exchange.”

“We see a future where theranostics will become a key pillar of modern cancer medicine, however a concerted effort is required globally by medical experts, industry, academia and governments. Collectively, we need to build on the great progress we have already made, to collaborate, knowledge-share, and increase patient access to new therapies in a faster and more affordable way,” said Professor Hicks.

In a busy week for GenesisCare, the organisation has also inked a multi-year strategic research partnership with Radiopharm Theranostics in an effort to develop novel radiopharmaceuticals and address unmet needs in oncology.

“Radiopharmaceuticals are quickly becoming a highly promising therapeutic frontier in oncology, offering new hope to patients who may have exhausted all other treatment options,” Radiopharm Theranostics CEO and managing director Riccardo Canevari said.

“We are delighted to be extending and strengthening our partnership with GenesisCare, a world leader in cancer care, to advance the future of radiopharmaceuticals and improve access to innovative therapies for patients all over the world.”

Dr Danielle Meyrick commented “We are delighted to be partnering with Radiopharm on its exciting pipeline of research in Australia. This R&D collaboration brings together two Australian-founded healthcare companies who share an interest in investigating and developing new therapies.”

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Aussie medtech forges ahead, making inroads with new technology

Aussie medtech forges ahead, making inroads with new technology

Health Industry Hub | February 23, 2024 |

MedTech & Diagnostics News: Adelaide-based medical technology firm, LBT Innovations has successfully delivered its cutting-edge Automated Plate Assessment System (APAS) […]

More


News & Trends - Pharmaceuticals

Is the imposed PBS funding cap driving the migraine medicines shortage?

Is the imposed PBS funding cap driving the migraine medicines shortage?

Health Industry Hub | February 23, 2024 |

Pharma News: Australia finds itself grappling with an unparalleled shortage of migraine prevention medicines, leaving a significant impact on the […]

More


News & Trends - Pharmaceuticals

MSAC rejects Janssen's CAR T therapy despite clinical superiority, citing need for 'substantial price reduction'

MSAC rejects Janssen’s CAR T therapy despite clinical superiority, citing need for ‘substantial price reduction’

Health Industry Hub | February 23, 2024 |

Pharma News: The Medical Services Advisory Committee (MSAC) has deferred its decision on whether Janssen’s CAR T-cell therapy Carvykti (cilta-cel) […]

More


News & Trends - Pharmaceuticals

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Health Industry Hub | February 23, 2024 |

Pharma News: The Therapeutic Goods Administration (TGA) has granted approval for the first endometriosis treatment in 13 years. Gedeon Richter […]

More


This content is copyright protected. Please subscribe to gain access.